skinny.

Latest / Breastcancer.org Podcast

Experimental Talazoparib Seems Better Than Chemotherapy for Metastatic HER2-Negative Disease in Women With a BRCA Mutation

Jennifer Litton, associate professor of breast Medical Oncology at the University of Texas MD Anderson Cancer Center, discusses the results of the EMBRACA study she presented at the 2017 San Antonio Breast Cancer Symposium showing that talazoparib, an experimental targeted therapy medicine, improved the time until the cancer grew in women with a BRCA1 or BRCA2 mutation who had been diagnosed with metastatic HER2-negative breast cancer compared to chemotherapy.

Listen to the podcast to hear Dr. Litton explain:

how talazoparib works

whether talazoparib will offer benefits to women with other…

Log in to save or queue this episode.

The skinny

The skinny isn't ready yet — notes appear once the transcript is processed.